Retifanlimab, marketed under the brand name Zynyz, was approved by the FDA on March 22, 2023.

AbbVie revealed that the European Commission has granted approval for SKYRIZI(risankizumab) to be used in adult patients suffering from moderately to severely active ulcerative colitis.

Rezafungin, marketed under the brand name Rezzayo, was approved by the FDA on March 22, 2023.

Chemomab Therapeutics Announces Positive Results in Phase 2 Study: CM-101 Demonstrates Anti-Fibrotic, Anti-Inflammatory, and Anti-Cholestatic Effects in Primary Sclerosing Cholangitis.

The FDA approved Daybue on March 10, 2023, for the treatment of Rett syndrome in adults and children aged 2 years and older.

The FDA has approved BioMarin's BRINEURA® (cerliponase alfa) for treating children under 3 years old with CLN2 disease.

The FDA approved Skyclarys on February 28, 2023, for the treatment of Friedreich's ataxia in adults and teenagers 16 years and older.

Jul 31st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The FDA approved Prevduo for use in adults and children at least 2 years old to help regain muscle function after surgery.

IASO Bio Receives NMPA Clearance for IASO-782 IND Application to Address Systemic Lupus Erythematosus (SLE).

The FDA granted approval to Altuviiio as a first-in-class, high-sustained factor VIII replacement therapy for hemophilia A patients on February 22, 2023.

Nkarta Reveals Start of Clinical Trial Led by Investigators for NKX019 in Treating Systemic Lupus Erythematosus.